SCHEMBL23824452

SCHEMBL23824452

CC(C)(C)OC(=O)NC(CC1CC1)C(=O)NC(C[C@@H]1CCCNC1=O)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 2/20 0.52
▸ CTSK P43235 2/20 0.52
▸ CTSL P07711 3/20 0.48
▸ CTSB P07858 2/20 0.48
▸ IDO1 P14902 1/20 0.44
▸ AAK1 Q2M2I8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29062824 1.00 CTSS (0.52) CTSSCTSKCTSLCTSBIDO1
SCHEMBL23824449 1.00 CTSS (0.52) CTSSCTSKCTSLCTSBIDO1
SCHEMBL29063284 0.94 CTSL (0.54) CTSSCTSKCTSLCTSBIDO1
SCHEMBL29063289 0.94 CTSL (0.54) CTSSCTSKCTSLCTSBIDO1
SCHEMBL29062838 0.94 CTSL (0.54) CTSSCTSKCTSLCTSBIDO1
SCHEMBL30009598 0.94 CTSL (0.54) CTSSCTSKCTSLCTSBIDO1
SCHEMBL19586956 0.92 IDO1 (0.50) CTSSCTSKCTSLIDO1
SCHEMBL19586958 0.92 IDO1 (0.50) CTSSCTSKCTSLIDO1
SCHEMBL19586954 0.92 IDO1 (0.50) CTSSCTSKCTSLIDO1
SCHEMBL23824331 0.91 CTSS (0.56) CTSSCTSKCTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 — — US disclosed
US-20230192663-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-06-22 — — US disclosed
EP-4161902-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2023-04-12 — — EP disclosed
WO-2023044462-A1 CYSTEINE PROTEASE INHIBITOR FORMULATIONS AND METHOD OF USE THEREOF Pardes Biosciences, Inc. (US) 2023-03-23 — — WO disclosed
US-20220402896-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2022-12-22 — — US disclosed
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-12-13 — — US disclosed
US-20220162194-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2022-05-26 — — US disclosed
US-11312704-B2 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-04-26 — — US disclosed
WO-2021252644-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2021-12-16 — — WO disclosed
US-20210355111-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2021-11-18 — — US disclosed
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-11-16 — — US disclosed
US-11124497-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312704-B2 Inhibitors of cysteine proteases and methods of use thereof CTSV, CTRL, CTSL CTSS 10/4885CTSK 49/4885CTSL 3/4885
US-20220162194-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSV, CTRL, CTSL CTSS 10/4885CTSK 49/4885CTSL 3/4885
US-20220402896-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSV, CTRL, CTSL CTSS 10/4885CTSK 49/4885CTSL 3/4885
US-20210355111-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSV, CTSL CTSS 7/4885CTSK 43/4885CTSL 3/4885
US-11124497-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL CTSS 6/4885CTSK 57/4885CTSL 3/4885
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL CTSS 7/4885CTSK 43/4885CTSL 3/4885
US-20230192663-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSV, CTRL, CTSL CTSS 10/4885CTSK 49/4885CTSL 3/4885
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL CTSS 7/4885CTSK 43/4885CTSL 3/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV CTSS 7/4885CTSK 46/4885CTSL 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback